帕博利珠单抗联合同步放化疗治疗不可切除III期非小细胞肺癌:2期KEYNOTE-799非随机试验
KEYNOTE-799是一项2期非随机两队列开放标签研究,纳入216例既往未治疗的不可切除IIIA/IIIB/IIIC期NSCLC患者,评估帕博利珠单抗联合同步放化疗的疗效与安全性。队列A客观缓解率为70.5%,队列B为70.6%,3级及以上肺炎发生率分别为8.0%和6.9%。研究表明该方案具有 promising 抗肿瘤活性且安全性可控。
要点
- 帕博利珠单抗联合同步放化疗在III期NSCLC中客观缓解率约70%。
- 3级及以上肺炎发生率在队列A为8.0%,队列B为6.9%。
- 3-5级治疗相关不良事件发生率分别为64.3%和50.0%。
核心结论
- 帕博利珠单抗联合同步放化疗在既往未治疗的局部晚期III期NSCLC中显示出有前景的抗肿瘤活性和可控的安全性。
研究设计与样本
- 2期、非随机、两队列、开放标签KEYNOTE-799研究,2018年11月5日至2020年7月31日从10个国家52个学术和社区机构入组216例患者。
- 队列A(鳞癌/非鳞癌)接受1周期卡铂(AUC 6 mg/mL/min)、紫杉醇(200 mg/m2)和帕博利珠单抗(200 mg),随后每周卡铂(AUC 2 mg/mL/min)和紫杉醇(45 mg/m2)共6周,以及2周期帕博利珠单抗联合标准胸部放疗。
- 队列B(非鳞癌)接受3周期顺铂(75 mg/m2)、培美曲塞(500 mg/m2)和帕博利珠单抗(200 mg)每3周一次,并在第2和3周期联合胸部放疗;患者额外接受14周期帕博利珠单抗。
主要发现
- 队列A客观缓解率为70.5%(79/112;95% CI,61.2%-78.8%),队列B为70.6%(72/102;95% CI,60.7%-79.2%)。
- 队列A中79.7%、队列B中75.6%的患者缓解持续时间达12个月或更长,中位缓解持续时间未达到。
- 队列A中9/112例(8.0%)、队列B中7/102例(6.9%)发生3级及以上肺炎。
- 队列A中72/112例(64.3%)、队列B中51/102例(50.0%)发生3-5级治疗相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) may provide treatment benefit to patients with locally advanced, stage III non-small cell lung cancer (NSCLC). OBJECTIVE: To evaluate treatment outcomes and safety of pembrolizumab plus cCRT in stage III NSCLC. DESIGN, SETTING, AND PARTICIPANTS: The phase 2, nonrandomized, 2-cohort, open-label KEYNOTE-799 study enrolled patients between November 5, 2018, and July 31, 2020, from 52 academic facilities and community-based institutions across 10 countries. As of October 28, 2020, median (range) follow-up was 18.5 (13.6-23.8) months in cohort A and 13.7 (2.9-23.5) months in cohort B. Of 301 patients screened, 216 eligible patients with previously untreated, unresectable, and pathologically/radiologically confirmed stage IIIA/IIIB/IIIC NSCLC with measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) were enrolled. INTERVENTIONS: Patients in cohort A (squamous/nonsquamous) received 1 cycle (3 weeks) of carboplatin (area under the curve [AUC] 6 mg/mL/min), paclitaxel (200 mg/m2), and pembrolizumab (200 mg), followed by carboplatin (AUC 2 mg/mL/min) and paclitaxel (45 mg/m2) once weekly for 6 weeks and 2 cycles of pembrolizumab plus standard thoracic radiotherapy. Patients in cohort B (nonsquamous) received 3 cycles of cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and pembrolizumab (200 mg) every 3 weeks and thoracic radiotherapy in cycles 2 and 3. Patients received 14 additional cycles of pembrolizumab. MAIN OUTCOMES AND MEASURES: Coprimary end points were objective response rate per RECIST v1.1 by blinded independent central review and incidence of grade 3 to 5 pneumonitis. RESULTS: A total of 112 patients received treatment in cohort A (76 men [67.9%]; median [range] age, 66.0 [46-90] years; 66 patients [58.9%] with programmed cell death ligand 1 [PD-L1] tumor proportion score ≥1%) and 102 patients received treatment in cohort B (62 men [60.8%]; median [range] age, 64.0 [35-81] years; 40 patients [39.2%] with PD-L1 tumor proportion score ≥1%). Objective response rate was 70.5% (79 of 112; 95% CI, 61.2%-78.8%) in cohort A and 70.6% (72 of 102; 95% CI, 60.7%-79.2%) in cohort B. Median duration of response was not reached, but 79.7% and 75.6%, respectively, had response duration of 12 months or longer. Grade 3 or higher pneumonitis occurred in 9 of 112 patients (8.0%) in cohort A and 7 of 102 (6.9%) in cohort B. Grade 3 to 5 treatment-related adverse events occurred in 72 of 112 (64.3%) and 51 of 102 (50.0%) patients, respectively. CONCLUSIONS AND RELEVANCE: The findings of this phase 2, nonrandomized, 2-cohort study suggest promising antitumor activity of pembrolizumab plus cCRT and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC.
引用
- Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021. PMID: 34086039. doi:10.1001/jamaoncol.2021.2301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。